好酸球性食道炎（EoE）- 市場考察、疫学、市場予測（2034年）

主なハイライト

• 主要7市場の好酸球性食道炎の総市場規模は2023年に約1兆8,000億米ドルであり、予測期間（2020年～2034年）に成長が見込まれます。
• 欧州4ヶ国・英国の中では、2034年にドイツが最大の収益シェアを獲得し、フランスと英国がこれに続く。
• 主要7市場では、2023年に好酸球性食道炎と診断された有病者数がもっとも多かったのは米国で、主要7市場全体の有病者数の約65%を占めました。この数字は予測期間（2024年～2034年）に増加する見込みです。
• DelveInsightの分析によると、好酸球性食道炎と診断された有病率は主要7市場の男性で高いことが明らかになっています。
• 年齢別では、18歳を超える患者が18歳未満の患者よりも高い有病率を示しています。
• プロトンポンプ阻害薬は好酸球性食道炎治療の基本です。
• 近年、DUPIXENT、EOHILIA、JORVEZAのような治療薬が主要7市場の国々でEoEの治療薬として承認されています。
• 好酸球性食道炎のパイプラインは強力で、VELSIPITY、TEZSPIRE、ESO-101、Cendakimabなどの多くの候補があります。
• 2024年2月、米国FDAは11歳以上のEoE患者に対する最初で唯一の経口治療薬であるEOHILIA（ブデソニド経口懸濁液）を承認しました。
• 2024年1月、米国FDAは体重15kg超の1～11歳の小児EoE患者の治療薬としてDUPIXENT（デュピルマブ）を承認しました。
• 2024年9月、Regeneron PharmaceuticalsとSanofiは、欧州医薬品庁の医薬品委員会（CHMP）が、欧州連合（EU）における1歳までの小児のEoEに対するDUPIXENT（デュピルマブ）の拡大承認を推奨する肯定的意見を採択したと発表しました。この推奨は、体重15kg以上の1～11歳の小児を対象としています。欧州委員会は今後数ヶ月以内に最終決定を発表する予定です。

好酸球性食道炎の市場見通し

好酸球性食道炎の市場は、特に新治療法の開発や青年と成人に対する包括的ガイドラインの確立など、大きなアンメットニーズによって牽引されています。プロトンポンプ阻害薬やコルチコステロイド療法のような現在の治療法は、症状を管理する一方、ステロイドの大量投与による深刻な副作用を伴います。近年、DUPIXENT、EOHILIA、JOrvezaのような治療薬が主要7市場の国々で承認されましたが、まだ大きな可能性があります。パイプラインには、センダキマブ、テゼペルマブ、APT-101、Etrasimodなど、臨床試験を進めている有望な治療薬があります。これらの新治療法は2025年までに市場に参入し、患者の転帰を大幅に改善し市場成長を促進する可能性のある疾患修飾の選択肢を提供すると予測されています。

主な調査結果

• 2023年、米国は好酸球性食道炎の主要7市場中最大の市場シェアを占め、市場全体の約75%を占めました。
• 2023年、米国ではDUPIXENTが好酸球性食道炎治療薬市場を独占しました。しかし、2034年までにセンダキマブが最大の市場シェアを占め、主導権を握ると予測されています。
• 2023年、好酸球性食道炎に対するプロトンポンプ阻害薬とステロイドの併用治療は、主要7市場の国々で約5億米ドルの収益を上げました。

当レポートでは、好酸球性食道炎（EoE）の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新薬などの情報を提供しています。

目次

第1章 重要考察

第2章 レポートのイントロダクション

第3章 EoE市場の概要

• 主要7市場のEoEの市場シェアの分布：国別（2023年）
• 主要7市場のEoEの市場シェアの分布：国別（2034年）

第4章 調査手法

第5章 エグゼクティブサマリー

第6章 重要な出来事

第7章 疾患の背景と概要

• イントロダクション
• EoEの原因と危険因子
• 兆候と症状
• 病態生理学
• バイオマーカー
• 診断
• 診断アルゴリズム
• 鑑別診断
• 診断ガイドライン

第8章 EoEの治療

• プロトンポンプ阻害薬
• ステロイド食道局所
• ダイエット療法
• 食道拡張
• 治療アルゴリズム

第9章 EoEの治療ガイドライン

• European Society for Paediatric Gastroenterology, Hepatology and Nutrition（ESPGHAN）のガイドライン
• AGA InstituteとJoint Task Force on Allergy-Immunology Practice ParametersのEoE管理の臨床ガイドライン

第10章 疫学と患者人口

• 主な調査結果
• 前提条件と根拠
• 主要7市場のEoEと診断された有病数
• 主要7市場のEoEを治療された患者
• 米国
• 欧州4ヶ国・英国
• 日本の疫学

第11章 ペイシェントジャーニー

第12章 上市済みの治療法

• 主な競合
• DUPIXENT（デュピルマブ）： Sanofi/Regeneron Pharmaceuticals
• JORVEZA（ブデソニド）： Dr. Falk Pharma GmbH
• EOHILIA（ブデソニド Oral Suspension）： Takeda

第13章 新治療法

• 主な競合
• TEZSPIRE（テゼペルマブ）： AstraZeneca/Amgen
• APT-1011（フルチカゾンプロピオン酸エステル）：Ellodi Pharmaceuticals
• Cendakimab（CC-93538/RPC4046）：Bristol Myers Squibb（BMS）
• IRL201104：Revolo Biotherapeutics
• ESO-101：EsoCap
• VELSIPITY（エトラシモド）：Pfizer

第14章 市場の分析

• 主な調査結果
• 市場見通し
• コンジョイント分析
• 主な市場予測の前提条件
• 主要7市場のEoEの総市場規模
• 主要7市場のEoEの市場規模：治療法別
• 米国の市場規模
  • 米国のEoEの総市場規模（2020年～2034年）
  • 米国のEoEの市場規模：治療法別（2020年～2034年）
• 欧州4ヶ国・英国の市場規模
  • 欧州4ヶ国・英国のEoEの総市場規模（2020年～2034年）
  • 欧州4ヶ国・英国のEoEの市場規模：治療法別（2020年～2034年）
• 日本の市場規模
  • 日本のEoEの総市場規模（2020年～2034年）
  • EoEの市場規模：治療法別

第15章 KOLの見解

第16章 SWOT分析

第17章 アンメットニーズ

第18章 市場参入と償還

• 米国
• 欧州4ヶ国・英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • 英国
• 日本
• EoEの市場参入と償還
  • DUPIXENT（デュピルマブ）：Sanofi/Regeneron Pharmaceuticals
  • JORVEZA（ブデソニド）：Dr. Falk Pharma GmbH
  • EOHILIA（ブデソニド経口懸濁液）：Takeda

第19章 付録

第20章 DelveInsightのサービス内容

第21章 免責事項

List of Tables

• Table 1: Summary of EoE Market, and Epidemiology (2023-2034)
• Table 2: BSG and BSPGHAN Joint Consensus Guidelines
• Table 3: EoE Diagnostic Criteria
• Table 4: EoETALY Consensus on the Diagnosis of EoE
• Table 5: European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Guidelines
• Table 6: Summary of European Statements and Recommendations on the Management of EoE
• Table 7: GRADE Definitions on Strength of Recommendation
• Table 8: GRADE Definitions on Quality of Evidence
• Table 9: American Gastroenterological Institute and Joint Task Force on Allergy-Immunology Practice Parameters Guideline Recommendations on the Management of EoE
• Table 10: Knowledge and Evidence Gaps in the Management of EoE
• Table 11: Total Diagnosed Prevalent Cases of EoE in the 7MM (2020-2034)
• Table 12: Total Treated Cases of EoE in the 7MM (2020-2034)
• Table 13: Total Diagnosed Prevalent Cases of EoE in the US (2020-2034)
• Table 14: Gender-specific Cases of EoE in the US (2020-2034)
• Table 15: Age-specific Cases of EoE in the US (2020-2034)
• Table 16: Total Treated Cases of EoE in the US (2020-2034)
• Table 17: Total Diagnosed Prevalent Cases of EoE in EU4 and the UK (2020-2034)
• Table 18: Gender-specific Cases of EoE in EU4 and the UK (2020-2034)
• Table 19: Age-specific Cases of EoE in EU4 and the UK (2020-2034)
• Table 20: Total Treated Cases of EoE in EU4 and the UK (2020-2034)
• Table 21: Total Diagnosed Prevalent Cases of EoE in Japan (2020-2034)
• Table 22: Gender-specific Cases of EoE in Japan (2020-2034)
• Table 23: Age-specific Cases of EoE in Japan (2020-2034)
• Table 24: Total Treated Cases of EoE in Japan (2020-2034)
• Table 25: Comparison of Marketed Drugs
• Table 26: Dosing Recommendations in EoE Patients
• Table 27: Patent Description for DUPIXENT
• Table 28: JORVEZA, Clinical Trial Description, 2024
• Table 29: Comparison of Emerging Drugs Under Development
• Table 30: TEZSPIRE (tezepelumab), Clinical Trial Description, 2024
• Table 31: APT-1011 (fluticasone propionate), Clinical Trial Description, 2024
• Table 32: Cendakimab (CC-93538/RPC4046),Clinical Trial Description, 2024
• Table 33: IRL201104, Clinical Trial Description, 2024
• Table 34: ESO-101, Clinical Trial Description, 2024
• Table 35: VELSIPITY (etrasimod), Clinical Trial Description, 2024
• Table 36: Key Market Forecast Assumption of EoE in the US
• Table 37: Key Market Forecast Assumption of EoE in EU4 and the UK
• Table 38: Key Market Forecast Assumption of EoE in Japan
• Table 39: Total Market Size of EoE in the 7MM in USD million (2020-2034)
• Table 40: Market Size of EoE by Therapies in the 7MM in USD million (2020-2034)
• Table 41: Total Market Size of EoE in the United States in USD million (2020-2034)
• Table 42: Market Size of EoE by Therapies in the United States in USD million (2020-2034)
• Table 43: Total Market Size of EoE in EU4 and the UK in USD million (2020-2034)
• Table 44: Market Size of EoE by Therapies in EU4 and the UK in USD million (2020-2034)
• Table 45: Total Market Size of EoE in Japan in USD million (2020-2034)
• Table 46: Market Size of EoE by Therapies in Japan in USD million (2020-2034)
• Table 47: DUPIXENT - Probability and Extent of Added Benefit
• Table 48: HAS Assessment for JORVEZA (SMR)
• Table 49: HAS Assessment for JORVEZA (ASMR)

List of Figures

• Figure 1: Role of Patient, Environmental, and Genetic Factors in the Development of EoE
• Figure 2: Disease Progression of EoE
• Figure 3: Pathophysiology of EoE
• Figure 4: Role of TSLP Gene in EoE Pathogenesis
• Figure 5: Endoscopic Features of EoE
• Figure 6: Diagnosis Algorithm for EoE
• Figure 7: Diagnosis and Management of EoE
• Figure 8: Updated EoE Diagnosis
• Figure 9: Treatment of EoE
• Figure 10: Treatment Algorithm of EoE
• Figure 11: Total Diagnosed Prevalent Cases of EoE in the 7MM (2020-2034)
• Figure 12: Total Treated Cases of EoE in the 7MM (2020-2034)
• Figure 13: Total Diagnosed Prevalent Cases of EoE in the US (2020-2034)
• Figure 14: Gender-specific Cases of EoE in the US (2020-2034)
• Figure 15: Age-specific Cases of EoE in the US (2020-2034)
• Figure 16: Total Treated Cases of EoE in the US (2020-2034)
• Figure 17: Total Diagnosed Prevalent Cases of EoE in EU4 and the UK (2020-2034)
• Figure 18: Gender-specific Cases of EoE in EU4 and the UK (2020-2034)
• Figure 19: Age-specific Cases of EoE in EU4 and the UK (2020-2034)
• Figure 20: Total Treated Cases of EoE in EU4 and the UK (2020-2034)
• Figure 21: Total Diagnosed Prevalent Cases of EoE in Japan (2020-2034)
• Figure 22: Gender-specific Cases of EoE in Japan (2020-2034)
• Figure 23: Age-specific Cases of EoE in Japan (2020-2034)
• Figure 24: Total Treated Cases of EoE in Japan (2020-2034)
• Figure 25: Total Market Size of EoE in the 7MM (2020-2034)
• Figure 26: Market Size of EoE by Therapies in the 7MM (2020-2034)
• Figure 27: Total Market Size of EoE in the US (2020-2034)
• Figure 28: Market Size of EoE by Therapies in the United States (2020-2034)
• Figure 29: Total Market Size of EoE in EU4 and the UK (2020-2034)
• Figure 30: Market Size of EoE by Therapies in EU4 and the UK (2020-2034)
• Figure 31: Total Market Size of EoE in Japan (2020-2034)
• Figure 32: Market Size of EoE by Therapies in Japan (2020-2034)
• Figure 33: Health Technology Assessment
• Figure 34: Reimbursement Process in Germany
• Figure 35: Reimbursement Process in France
• Figure 36: Reimbursement Process in Italy
• Figure 37: Reimbursement Process in Spain
• Figure 38: Reimbursement Process in the United Kingdom
• Figure 39: Reimbursement Process in Japan

Key Highlights:

• The total market size of eosinophilic esophagitis in 2023 was approximately USD 1,800 billion in the 7MM, which is expected to grow during the forecast period (2020-2034).
• Among EU4 and the UK, Germany will capture the maximum revenue share, followed by France and UK in 2034.
• In the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2023, with around 65% of the total diagnosed prevalent cases across the 7MM; these numbers are expected to increase during the forecast period (2024-2034).
• DelveInsight's analysis reveals that a higher diagnosed prevalence of eosinophilic esophagitis is observed in the male gender across the 7MM.
• Among age-specific cases, patient with more than 18 yrs of age represents a higher prevalence compared to patient with less than 18 yrs of age.
• Proton Pump Inhibitors have been the cornerstone of eosinophilic esophagitis management
• In recent years therapies like DUPIXENT, EOHILIA, JORVEZA have been approved for the treatment of EoE in the 7MM countries.
• The pipeline for Eosinophilic Esophagitis is strong, with many candidates like VELSIPITY, TEZSPIRE, ESO-101, Cendakimab and others.
• In February 2024, the US FDA approved EOHILIA (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with EoE.
• In January 2024, US FDA approved DUPIXENT (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with EoE.
• In September 2024, Regeneron Pharmaceuticals and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the expanded approval of DUPIXENT (dupilumab) in the European Union for EoE in children down to 1 year of age. The recommendation is for children aged 1-11 years who weigh at least 15 kg. The European Commission is expected to announce a final decision in the coming months.

DelveInsight's " Eosinophilic Esophagitis (EoE)- Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Eosinophilic Esophagitis historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Eosinophilic Esophagitis market report provides current treatment practices, emerging drugs, Eosinophilic Esophagitis market share of individual therapies, and current and forecasted Eosinophilic Esophagitis market size from 2020 to 2034, segmented by seven major markets. The report also covers current Eosinophilic Esophagitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Eosinophilic Esophagitis (EoE): Understanding and Treatment Algorithm

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis (EoE) is an emerging chronic inflammatory disease of the esophagus characterized by upper gastrointestinal symptoms, including dysphagia and esophageal food impaction. The histopathological manifestations involve intraepithelial infiltration of eosinophils (=15 Eos/HPF) and remodeling of the esophageal epithelium, including Basal Zone Hyperplasia (BZH) and Dilated Intercellular Spaces (DIS), which can lead to strictures and narrow-caliber esophagus.

EoE is a complex disease characterized by heterogeneous clinical presentation (age of onset, symptomology, varying clinical manifestations and comorbidities, natural history, and responsiveness to therapy). Despite challenges in disease diagnosis and management, there is corroborative clinical and experimental evidence to suggest that EoE is driven by an underlying CD4+ T helper type 2 (Th2) allergic inflammatory response to dietary food allergens in the esophageal mucosa. EoE-derived signals (e.g., Thymic Stromal Lymphopoietin (TSLP) and interleukin (IL-13) are thought to induce Type-2 allergic cytokines, including IL-5 and IL-13, which stimulate the recruitment and activation of the allergic effector cells, eosinophils, and mast cells. Eosinophil and mast cell-derived mediators stimulate dysregulation of epithelial barrier regulatory and proliferative response genes within the esophageal epithelial compartment leading to esophageal epithelial remodeling and fibrosis. Compelling evidence supporting a role for allergic inflammatory cells (CD4+ Th2-type cells, eosinophils, and mast cells) and cytokines in EoE has led to using biologics that target these inflammatory cells and mediators as potential treatments for EoE.

Eosinophilic Esophagitis Diagnosis

EoE is characterized by clinical symptoms of esophageal dysfunction and esophageal eosinophilia, defined by =15 Eosinophils per High-powered Field (Eos/HPF) on biopsy. Before solidifying a diagnosis of EoE, clinicians should consider other etiologies of esophageal eosinophilia.

Endoscopy, Barium Esophagram, Reflux testing, Impedence planimetry and others methods are used for the diagnosis of EoE.

Eosinophilic Esophagitis Treatment

The treatment of EoE seeks to relieve symptoms, improve histopathology, reverse existing disease complications, and prevent future disease consequences. The primary approach involves treatment with Proton pump inhibitors, swallowed topical steroids, and diet therapy. Medical and diet therapies that significantly reduce esophageal inflammation may not effectively reverse existing esophageal strictures. In contrast, esophageal dilation can effectively manage esophageal strictures, thereby alleviating dysphagia in the absence of improvement in esophageal inflammation. Endoscopic features, as delineated by the EREFS system, identify remodeling aspects of the disease, including esophageal rings and strictures that are associated with symptom outcomes of dysphagia and food impaction risk and are not verifiable on mucosal biopsies.

Eosinophilic Esophagitis Epidemiology

The Eosinophilic Esophagitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the Total Diagnosed Prevalent Cases of Eosinophilic Esophagitis, Gender-specific Cases of Eosinophilic Esophagitis, Age-specific Cases of Eosinophilic Esophagitis, Treated Cases of Eosinophilic Esophagitis in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

• In the 7MM, the US accounted for the highest diagnosed prevalent cases of eosinophilic esophagitis in 2023, with around 445,000 cases; these numbers are expected to increase during the forecast period.
• Eosinophilic Esophagitis predominantly affected males, with approximately 290,000 males diagnosed compared to 156,000 females in 2023 in the US.
• In the 7MM, individuals over the age of 18 were the most affected by Eosinophilic Esophagitis, with approximately 156,000 cases reported in 2023.

Eosinophilic Esophagitis Drug Chapters

The drug chapter segment of the Eosinophilic Esophagitis report encloses a detailed analysis of the marketed, late-stage (Phase III), and mid-stage (Phase II) pipeline drugs. The marketed drugs segment encloses DUPIXENT, EOHILIA, JORVEZA. Furthermore, the current key players for emerging drugs and their respective drug candidates include Celgene (Cendakimab), Astrazeneca & Amgen (Tezspire), Pfizer (Velsipity), Ellodi pharmaceuticals (APT-1011), EsoCap (ESO-101) and others. The drug chapter also helps understand the Eosinophilic Esophagitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, and the latest news and press releases.

Marketed Drugs

DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant. It is approved for the treatment of DUPIXENT, which was invented using Regeneron's proprietary VelocImmune technology, is a fully human monoclonal antibody that inhibits the signaling of the Interleukin-4 (IL-4) and Interleukin-13 (IL-13) pathways and is not an immunosuppressant.

In January 2024, US FDA approved DUPIXENT (dupilumab) for the treatment of pediatric patients aged 1 to 11 years, weighing at least 15 kg, with EoE andIn May 2022, US FDA approved DUPIXENT (dupilumab) to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 Kg. In January 2023, the European Commission expanded the marketing authorization for DUPIXENT (dupilumab) in the European Union to treat EoE in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Emerging Drugs

Cendakimab (CC-93538/RPC4046): Bristol Myers Squibb (BMS)

Cendakimab/RPC4046/CC-93538 is a recombinant humanized, high affinity, selective, anti-IL-13 mAb. RPC4046 binds an IL-13 epitope that prevents its binding to both IL-13R (alpha) 1 and IL-13R (alpha) 2, providing potential efficacy and/or safety advantages. The drug has been granted ODD for the treatment of EoE by the US FDA. In the Phase II study, RPC4046 demonstrated positive results. Currently, the company is conducting two Phase III clinical studies to evaluate the efficacy and safety of CC-93538 in adult and adolescent participants with EoE.

TEZSPIRE (Tezepelumab) : AstraZeneca/Amgen

TEZSPIRE (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP. This key epithelial cytokine sits at the top of multiple inflammatory cascades. It is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation associated with severe asthma, including airway hyperresponsiveness. TEZSPIRE acts at the top of the inflammation cascade and has the potential to help address a broad population of severe asthma patients irrespective of biomarker levels.

TEZSPIRE is approved in the US, EU, Japan, and other countries for the treatment of severe asthma. TEZSPIRE is also in development for other potential indications, including Chronic Obstructive Pulmonary Disease (COPD), chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and EoE. In October 2021, tezepelumab was granted an Orphan Drug Designation (ODD) by the FDA for the treatment of EoE.

Eosinophilic Esophagitis Market Outlook

The market for Eosinophilic Esophagitis is driven by significant unmet needs, particularly in the development of novel treatments and the establishment of comprehensive guidelines for adolescents and adults. Current treatments, like proton pump inhibitors and corticosteroids therapy, manage symptoms but come with serious side effects due to high steroid dosages. Although in recent years therapies like DUPIXENT, EOHILIA and JOrveza got approved in 7MM countries but still there is huge scope for emerging. There are some promising therapies in the pipeline, including Cendakimab, Tezepelumab, APT-101, Etrasimod and others which are advancing through clinical trials. These emerging therapies are expected to enter the market by 2025, offering potentially disease-modifying options that could significantly improve patient outcomes and drive market growth.

Key Findings

• In 2023, the United States held the largest market share for Eosinophilic Esophagitis among the 7MM, accounting for approximately 75% of the total market.
• In 2023, DUPIXENT dominated the Eosinophilic Esophagitis therapy market in the United States. However, by 2034, Cendakimab is expected to take the lead, commanding the largest market share.
• In 2023, Proton Pump Inhibitor and steroid combination treatments for Eosinophilic Esophagitis generated approximately USD 500 million in revenue across the 7MM countries.

Eosinophilic Esophagitis Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2024-2034, which depends on the competitive landscape, safety, and efficacy data along with order of entry. It is important to understand that the key players evaluating their novel therapies in the pivotal and confirmatory trials should remain vigilant when selecting appropriate comparators to stand the greatest chance of a positive opinion from regulatory bodies, leading to approval, smooth launch, and rapid uptake.

Eosinophilic Esophagitis Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III, Phase II, and Phase I/II. It also analyzes key players involved in developing targeted therapeutics. Companies like Astrazeneca/Amgen, Pfizer, BMS, EsoCap and others are actively engaging their product in research and development efforts for Eosinophilic Esophagitis. The pipeline of Eosinophilic Esophagitis possesses many potential drugs and there is a positive outlook for the therapeutics market, with expectations of growth during the forecast period (2024-2034).

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Eosinophilic Esophagitis emerging therapy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on the Eosinophilic Esophagitis evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Endocrinologist, Pediatricians, and others.

DelveInsight's analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers such as the National Institutes of Health, Cincinnati Children's Hospital Medical Center, Boston Children's Hospital, Great Ormond Street Hospital, etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Eosinophilic Esophagitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

The report provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of Eosinophilic Esophagitis, explaining its causes, signs, symptoms, pathogenesis, and currently used therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• Additionally, an all-inclusive account of the emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the Eosinophilic Esophagitis market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and KOL views, patient journey, and treatment preferences that help shape and drive Eosinophilic Esophagitis market.

Eosinophilic Esophagitis Report Insights

• Patient Population
• Therapeutic Approaches
• Eosinophilic Esophagitis Pipeline Analysis
• Eosinophilic Esophagitis Market Size and Trends
• Existing and Future Market Opportunity

Eosinophilic Esophagitis Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Eosinophilic Esophagitis Epidemiology Segmentation
• Key Cross Competition
• Drugs Uptake and Key Market Forecast Assumptions

Eosinophilic Esophagitis Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

• What was the Eosinophilic Esophagitis market size, the market size by therapies, market share (%) distribution in 2020, and what would it look like by 2034? What are the contributing factors for this growth?
• What can be the future treatment paradigm for Eosinophilic Esophagitis?
• What are the disease risks, burdens, and unmet needs of Eosinophilic Esophagitis? What will be the growth opportunities across the 7MM concerning the patient population with Eosinophilic Esophagitis?
• What are the current options for the treatment of Eosinophilic Esophagitis? What are the current guidelines for treating Eosinophilic Esophagitis in the 7MM?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitations of existing therapies?
• What is the patient share in Eosinophilic Esophagitis?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Eosinophilic Esophagitis market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Highlights of access and reimbursement policies of current therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. EoE Market Overview at a Glance

• 3.1. Market Share (%) Distribution of EoE by Country in 2023 in the 7MM
• 3.2. Market Share (%) Distribution of EoE by Country in 2034 in the 7MM

4. Methodology

5. Executive Summary

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Causes and Risk Factors of EoE
  • 7.2.1. Phenotypes and Endotypes
• 7.3. Signs and Symptoms
• 7.4. Pathophysiology
• 7.5. Biomarkers
• 7.6. Diagnosis.
  • 7.6.1. Endoscopy
  • 7.6.2. Barium Esophagram
  • 7.6.3. Reflux Testing
  • 7.6.4. Impedance Planimetry
• 7.7. Diagnostic Algorithm
• 7.8. Differential Diagnosis
• 7.9. Diagnosis Guidelines
  • 7.9.1. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology, and Nutrition (BSPGHAN) Joint Consensus Guidelines on the Diagnosis and Management of EoE in Children and Adults
  • 7.9.2. Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference
  • 7.9.3. The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis

8. Treatment of EoE

• 8.1. Proton Pump Inhibitors
• 8.2. Swallowed Topical Steroids
• 8.3. Diet Therapy
• 8.4. Esophageal Dilation
• 8.5. Treatment Algorithm

9. Treatment Guidelines for EoE

• 9.1. European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Guidelines
• 9.2. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of EoE

10. Epidemiology and Patient Population

• 10.1. Key Findings
• 10.2. Assumptions and Rationale
• 10.3. Total Diagnosed Prevalent cases of EoE in the 7MM
• 10.4. Total Treated Cases of EoE in the 7MM
• 10.5. The United States
  • 10.5.1. Total Diagnosed Prevalent Cases of EoE in the United States
  • 10.5.2. Gender-specific Cases of EoE in the United States
  • 10.5.3. Age-specific Cases of EoE in the United States
  • 10.5.4. Total Treated Cases of EoE in the United States
• 10.6. EU4 and the UK
  • 10.6.1. Total Diagnosed Prevalent Cases of EoE in EU4 and the UK
  • 10.6.2. Gender-specific Cases of EoE in EU4 and the UK
  • 10.6.3. Age-specific Cases of EoE in EU4 and the UK
  • 10.6.4. Total Treated Cases of EoE in EU4 and the UK
• 10.7. Japan Epidemiology
  • 10.7.1. Total Diagnosed Prevalent Cases of EoE in Japan
  • 10.7.2. Gender-specific Cases of EoE in Japan
  • 10.7.3. Age-specific Cases of EoE in Japan
  • 10.7.4. Total Treated Cases of EoE in Japan

11. Patient Journey

12. Marketed Therapies

• 12.1. Key Cross Competition
• 12.2. DUPIXENT (Dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 12.2.1. 1.2.1 Product Description
  • 12.2.2. 1.2.2 Regulatory Milestones
  • 12.2.3. 1.2.3 Other Developmental Activities
  • 12.2.4. 1.2.4 Safety and Efficacy
• 12.3. JORVEZA (Budesonide): Dr. Falk Pharma GmbH
  • 12.3.1. 1.3.1 Product Description
  • 12.3.2. 1.3.2 Regulatory Milestones
  • 12.3.3. 1.3.3 Other Developmental Activities
  • 12.3.4. 1.3.4 Clinical Developmental Activities
  • 12.3.5. 1.3.5 Safety and Efficacy
• 12.4. EOHILIA (Budesonide Oral Suspension): Takeda
  • 12.4.1. 1.4.1 Product Description
  • 12.4.2. 1.4.2 Regulatory Milestones
  • 12.4.3. 1.4.3 Other Developmental Activities
  • 12.4.4. 1.4.4 Safety and Efficacy

13. Emerging Therapies

• 13.1. Key Cross Competition
• 13.2. TEZSPIRE (Tezepelumab) : AstraZeneca/Amgen
  • 13.2.1. Product Description
  • 13.2.2. Other Developmental Activities
  • 13.2.3. Clinical Developmental Activities
  • 13.2.4. Analyst View
• 13.3. APT-1011 (Fluticasone Propionate): Ellodi Pharmaceuticals
  • 13.3.1. Product Description
  • 13.3.2. Other Developmental Activities
  • 13.3.3. Clinical Developmental Activities
  • 13.3.4. Safety and Efficacy
  • 13.3.5. Analyst View
• 13.4. Cendakimab (CC-93538/RPC4046): Bristol Myers Squibb (BMS)
  • 13.4.1. Product Description
  • 13.4.2. Other Developmental Activities
  • 13.4.3. Clinical Developmental Activities
  • 13.4.5. Safety and Efficacy
  • 13.4.6. Analyst View
• 13.5. IRL201104: Revolo Biotherapeutics
  • 13.5.1. Product Description
  • 13.5.2. Other Developmental Activities
  • 13.5.3. Clinical Developmental Activities
  • 13.5.4. Safety and Efficacy
  • 13.5.5. Analyst View
• 13.6. ESO-101 : EsoCap
  • 13.6.1. Product Description
  • 13.6.2. Other Developmental Activities
  • 13.6.3. Clinical Developmental Activities
  • 13.6.4. Safety and Efficacy
  • 13.6.5. Analyst View
• 13.7. VELSIPITY (Etrasimod): Pfizer
  • 13.7.1. Product Description
  • 13.7.2. Other Developmental Activities
  • 13.7.3. Clinical Developmental Activities
  • 13.7.5. Safety and Efficacy
  • 13.7.6. Analyst View

14. Market Analysis

• 14.1. Key Findings
• 14.2. Market Outlook
• 14.3. Conjoint Analysis
• 14.4. Key Market Forecast Assumptions
• 14.5. Total Market Size of EoE in the 7MM
• 14.6. Total Market Size of EoE by Therapies in the 7MM
• 14.7. United States Market Size
  • 14.7.1. Total Market Size of EoE in the US (2020-2034)
  • 14.7.2. Market Size of EoE by Therapies in the United States (2020-2034)
• 14.8. EU4 and the UK Market Size
  • 14.8.1. Total Market Size of EoE in EU4 and the UK (2020-2034)
  • 14.8.2. Market Size of EoE by Therapies in EU4 and the UK (2020-2034)
• 14.9. Japan Market Size
  • 14.9.1. Total Market Size of EoE in Japan (2020-2034)
  • 14.9.2. Market Size of EoE by Therapies

15. KOL Views

16. SWOT Analysis

17. Unmet Needs

18. Market Access and Reimbursement

• 18.1. United States
  • 18.1.1. Centre for Medicare and Medicaid Services (CMS)
• 18.2. EU4 and the UK
  • 18.2.1. Germany.
  • 18.2.2. France.
  • 18.2.3. Italy.
  • 18.2.4. Spain.
  • 18.2.5. United Kingdom
• 18.3. Japan.
  • 18.3.1. MHLW.
• 18.4. Market Access and Reimbursement of EoE
  • 18.4.1. DUPIXENT (Dupilumab): Sanofi/Regeneron Pharmaceuticals
  • 18.4.2. JORVEZA (Budesonide): Dr. Falk Pharma GmbH
  • 18.4.3. EOHILIA (Budesonide Oral Suspension): Takeda

19. Appendix

• 19.1. Bibliography
• 19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer